Free Trial
NASDAQ:SLS

SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

SELLAS Life Sciences Group logo
$1.94 +0.13 (+6.87%)
As of 02:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About SELLAS Life Sciences Group Stock (NASDAQ:SLS)

Key Stats

Today's Range
$1.79
$1.97
50-Day Range
$1.54
$2.19
52-Week Range
$0.77
$2.27
Volume
1.41 million shs
Average Volume
2.54 million shs
Market Capitalization
$204.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

SELLAS Life Sciences Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

SLS MarketRank™: 

SELLAS Life Sciences Group scored higher than 58% of companies evaluated by MarketBeat, and ranked 454th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    SELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.

  • Read more about SELLAS Life Sciences Group's stock forecast and price target.
  • Earnings Growth

    Earnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.57) to ($0.42) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SELLAS Life Sciences Group is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SELLAS Life Sciences Group is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SELLAS Life Sciences Group has a P/B Ratio of 7.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about SELLAS Life Sciences Group's valuation and earnings.
  • Percentage of Shares Shorted

    26.84% of the float of SELLAS Life Sciences Group has been sold short.
  • Short Interest Ratio / Days to Cover

    SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in SELLAS Life Sciences Group has recently decreased by 4.79%, indicating that investor sentiment is improving.
  • Dividend Yield

    SELLAS Life Sciences Group does not currently pay a dividend.

  • Dividend Growth

    SELLAS Life Sciences Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.84% of the float of SELLAS Life Sciences Group has been sold short.
  • Short Interest Ratio / Days to Cover

    SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in SELLAS Life Sciences Group has recently decreased by 4.79%, indicating that investor sentiment is improving.
  • News Sentiment

    SELLAS Life Sciences Group has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for SELLAS Life Sciences Group this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SELLAS Life Sciences Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,600.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of SELLAS Life Sciences Group is held by insiders.

  • Percentage Held by Institutions

    Only 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.

  • Read more about SELLAS Life Sciences Group's insider trading history.
Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLS Stock News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
See More Headlines

SLS Stock Analysis - Frequently Asked Questions

SELLAS Life Sciences Group's stock was trading at $1.04 on January 1st, 2025. Since then, SLS shares have increased by 81.3% and is now trading at $1.8850.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01.

Shares of SELLAS Life Sciences Group reverse split on the morning of Friday, November 8th 2019.The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Top institutional shareholders of SELLAS Life Sciences Group include Marshall Wace LLP (2.72%), Geode Capital Management LLC (2.21%), Rhumbline Advisers (0.14%) and XTX Topco Ltd (0.08%).
View institutional ownership trends
.

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include (UNISQ) (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol Myers Squibb (BMY) and AbbVie (ABBV).

Company Calendar

Last Earnings
8/12/2025
Today
8/27/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLS
CIK
1390478
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$7.00
Potential Upside/Downside
+284.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.88 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-132.51%
Return on Assets
-92.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.91
Quick Ratio
4.91

Sales & Book Value

Annual Sales
$1 million
Price / Sales
191.65
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.25 per share
Price / Book
7.28

Miscellaneous

Outstanding Shares
105,300,000
Free Float
104,033,000
Market Cap
$191.65 million
Optionable
Not Optionable
Beta
2.26

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SLS) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners